| Expression pattern: |
UP |
| Associated gene: |
CHD1, Ago2 |
| Associated microRNA: |
miR-449b-5p |
| Biological function: |
promotes proliferation and aerobic glycolysis; inhibits apoptosis; promotes tumor growth |
| Molecular mechanism: |
acts as an miRNA sponge for miR-449b-5p to regulate CHD1 expression |
| Biological pathway or process: |
proliferation (promotes); glycolysis (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; EdU Staining; Annexin V/PI Flow Cytometry; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
high expression of circLDLR was correlated with advanced tumor stage and poor differentiation of TNM; potential target for early diagnosis and clinical treatment of GC |
| Description: |
circLDLR (hsa_circ_0006877), derived from LDLR, is up-regulated in gastric cancer tissues and GC cell lines and is mainly localized in the cytoplasm. It promotes GC cell proliferation and aerobic glycolysis and inhibits apoptosis by sponging miR-449b-5p to derepress CHD1, and circLDLR knockdown suppresses xenograft tumor growth. |
| Confidence score: |
0.8439 |